Traduction de «plante de jours longs » (Français → Anglais) :

‘In cases where it is found that, after completion of the formalities referred to in point (a), the products have remained, except in cases of force majeure, for more than 28 days for the purpose of transhipment in one or more other airports in the customs territory of the Community, the day, or days, by which the 28-day time limit is exceeded shall, for the purposes of Article 50, be deemed days by which the time limit laid down in Article 7 is exceeded’.

The longest average transfer times were from Sweden (4.61 days), the UK (4.19 days) and Denmark (4.07 days).

(b) In cases where it is found that, after completion of the formalities referred to in point (a), the products have remained, except in cases of force majeure, for more than 28 days for the purpose of transhipment in one or more other airports in the customs territory of the Community, the day, or days, by which the 28-day time limit is exceeded shall, for the purposes of Articles 35 and 50, be deemed days by which the time limit laid down in Articles 7 and 34 is exceeded.

The longest average transfer times were from Sweden (4.61 days), the UK (4.19 days) and Denmark (4.07 days). The shortest were from Ireland (1.67 days), Greece (1.82 days) and France (1.99 days).

- MEDICINAL PLANT PREPARATIONS "THE COUNCIL OF THE EUROPEAN UNION, Having regard to the Treaty establishing the European Community, Whereas, in its Resolution of 30 November 1995 on the integration of health protection requirements in Community policies, the Council considers that the Community must pay particular attention to the impact on health of action proposed in a number of areas, including free movement of goods; Whereas action to improve understanding of and address the effects on human health of the free movement of goods, in particular the free movement of medicinal products, should form part of the Community's overall strategy for action in the field of public health; Considering the wider use of medicinal ...[+++]plants in medical treatment in the European Union; Considering the growing use of medicinal plants in the European Union; Considering the impact of medicinal plant preparations on public health and the recommendations of the World Health Organization; Considering the heterogeneity of the commercial presentation of those preparations on the market; Whereas the safeguarding of public health must be a priority objective at Community level; Whereas it is also necessary to pay appropriate attention to conditions which will ensure that the development of industry and the free movement of such products within the European Union are not hindered; Considering the specific problems involved in checking raw materials and medicinal plant preparations from third countries in order to guarantee their quality; Whereas it is appropriate to take into account the special characteristics of such preparations; Whereas it is necessary to guarantee the protection of consumers' health throughout the whole process of manufacture, distribution and putting up for sale, CALLS ON the Commission, in close cooperation with the Member States, to study the situation that exists and, in particular: - whether there are public health concerns over medicinal plant preparations ...

This comparison shall enable the applicant to identify unintended effects resulting from the genetic modification and shall address also plant biology and agronomic traits, including common breeding parameters (such as yield, plant morphology, flowering time, day degrees to maturity, duration of pollen viability, response to plant pathogens and insect pests, sensitivity to abiotic stress).